La diabetes altera el potencial osteogénico de células progenitoras de médula ósea: efectos del tratamiento con metformina

cic.institucionOrigenLaboratorio de Investigación en Osteopatías y Metabolismo Minerales
cic.isFulltexttruees
cic.isPeerReviewedtruees
cic.lugarDesarrolloLaboratorio de Investigación en Osteopatías y Metabolismo Minerales
cic.versioninfo:eu-repo/semantics/publishedVersiones
dc.date.accessioned2021-10-07T17:20:54Z
dc.date.available2021-10-07T17:20:54Z
dc.identifier.urihttps://digital.cic.gba.gob.ar/handle/11746/11320
dc.titleLa diabetes altera el potencial osteogénico de células progenitoras de médula ósea: efectos del tratamiento con metforminaes
dc.typeArtículoes
dcterms.abstractEn este trabajo, estudiamos el efecto de una Diabetes inducida por destrucción parcial de la masa de células beta pancreáticas, sobre el compromiso osteogénico de células progenitoras de médula ósea (CPMO), y su modulación por el tratamiento oral con Metformina. Para ello utilizamos ratas Sprague Dawley, divididas en cuatro grupos: controles [C], controles tratadas con Metformina [M], diabéticas [D], y diabéticas tratadas con Metformina [DM]. La inducción de Diabetes se realizó, por inyección intraperitoneal sucesiva de ácido nicotínico y estreptozotocina. Sobre los cultivos de CPMO se evaluó la actividad específica de Fosfatasa Alcalina (FAL) y la producción de Colágeno tipo 1 (Col-1) en estado basal y en medio de diferenciación osteogénico luego de 15 días. A los 21 días, se evaluaron los depósitos de mineral extracelular. La FAL y el Col-1 de CPMO basales, no mostraron diferencias significativas entre los cuatro grupos experimentales. Al cabo de 15 días, las CPMO de ratas M mostraron un incremento en el Col-1 de 122 % respecto de C; D 30 % respecto de C y DM 68 % respecto de C. La FAL expresó un 171 % para M, 34 % para D; y 125 % para DM todos respecto de C. Luego de 21 días, se observó una disminución en la mineralización de las CPMO de D (65 % respecto del grupo C). El tratamiento con metformina incrementó la mineralización de las CPMO en todos los casos. En conclusión, en nuestro modelo experimental de Diabetes, ésta disminuye el potencial osteogénico de las CPMO, un efecto que es parcialmente revertido por el tratamiento oral con Metformina. Estos hallazgos podrían explicar, al menos en parte, las alteraciones óseas descriptas en el hueso asociadas con la Diabetes.es
dcterms.abstractDiabetes mellitus is associated with an increased incidence of skeletal abnormalities, resulting in lower bone formation and/or remodeling. Osteopenia, osteoporosis and an increased incidence of non-traumatic fractures has been particularly observed in patients with type 2 diabetes. Recently, we have demonstrated that metformin has in vitro and in vivo osteogenic effects: (a) it stimulates the proliferation, differentiation and mineralization of osteoblasts in culture, and (b) in non-diabetic rats, it increases the repair of minimal bone lesions and improves femoral trabecular bone microarchitecture. In this study, we evaluated in rats the effect of diabetes induction by a partial destruction of pancreatic beta cells, on the osteogenic commitment of bone marrow progenitor cells (BMPC), and the modulation of this effect by orally administered metformin. We used young male Sprague Dawley rats (200 g), divided into four groups: untreated non-diabetic controls [C], non-diabetic rats treated for 2 weeks with metformin administered in drinking water (100 mg/kg/day) [M], untreated diabetic rats [D], and diabetic rats treated for 2 weeks with metformin (100 mg/kg/day) [DM]. Induction of Diabetes was performed one week prior to treatment with metformin, by successive intraperitoneal injections with 75 mg/kg body weight of nicotinic acid and 60 mg/kg body weight of streptozotocin. At the end of all treatments, blood samples were obtained to confirm the development of Diabetes, after which the animals were sacrificed by cervical dislocation under anesthesia. Femora and/or tibiae were dissected, and bone marrow cells were collected by flushing the bone diaphysal canal with Dulbecco’s modified essential medium (DMEM) under sterile conditions. Adherent cells were grown to confluence in DMEM-10 % fetal bovine serum (FBS), after which we assessed alkaline phosphatase specific activity (ALP) by an enzymatic kinetic method, and type 1 collagen production (Col-1) by a Sirius Red colorimetric method (basal osteoblastic differentiation of BMPC). Subsequently, BMPC were submitted to an osteogenic induction for 15 days with an osteogenic medium (DMEM-10 % FBS containing ascorbic acid and sodium beta-glycerophosphate), after which ALP and Col-1 were evaluated. Basal ALP activity and type 1 collagen production (BMPC without osteogenic differentiation) showed no significant differences between the four experimental groups. After 15 days of culture in osteogenic medium, BMPC from control rats increased their expression of ALP (5 times compared to baseline) and collagen production (11 times compared to baseline). BMPC from diabetic rats after 15 days culture in osteogenic medium, also showed a significant (although smaller) increase in ALP (2-3 fold over basal activity) and collagen production (4-fold compared to baseline). BMPC obtained from rats treated with metformin (groups M and DM) and submitted to osteogenic induction for 15 days, showed an approximately 2-4-fold increase in both ALP and Col-1 (when compared with groups C and D, respectively). After 21 days of osteogenic induction, a decrease was observed in the mineralization of BMPC obtained from group D (65 % of that for group C). Treatment with metformin increased the mineralizing capacity of BMPC in all cases, including a reversal of the inhibitory effect of Diabetes on this parameter. In conclusion, we have found that our model of Diabetes reduces the osteogenic potential of bone marrow progenitor cells, and that this effect is partially reverted by orally administered metformin. These findings could explain, at least in part, the bone alterations that have been associated with Diabetes mellitus.en
dcterms.alternativeDiabetes decreases the osteogenic potential of bone marrow progenitor cells: effects of treatment with metforminen
dcterms.creator.authorTolosa, M. J.es
dcterms.creator.authorChuguransky, S. R.es
dcterms.creator.authorSchurman, Leónes
dcterms.creator.authorSedlinsky, Claudiaes
dcterms.creator.authorCortizo, Ana Maríaes
dcterms.creator.authorMcCarthy, Antonio Desmondes
dcterms.creator.authorMolinuevo, María Silvinaes
dcterms.extent70-76es
dcterms.identifier.urlRecurso onlinees
dcterms.isPartOf.issuevol. 49, no. 2es
dcterms.isPartOf.seriesRevista Argentina de Endocrinología y Metabolismoes
dcterms.issued2012
dcterms.languageEspañoles
dcterms.licenseAttribution-NonCommercial 4.0 International (BY-NC 4.0)es
dcterms.subjectDiabetes Mellituses
dcterms.subjectCélulas progenitoras de médula óseaes
dcterms.subjectHuesoses
dcterms.subjectMetforminaes
dcterms.subjectBone marrow progenitor cellsen
dcterms.subjectBoneen
dcterms.subjectMetforminen
dcterms.subject.materiaCiencias Biológicases
Archivos
Paquete original
Mostrando1 - 1 de 1
Imagen en miniatura
Nombre:
2012_Tolosa MJ_Rev Arg Endocrinol Metab.pdf-PDFA.pdf
Tamaño:
623.12 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento completo